Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Singular Health inks US physician network deal
Clarity clearly is undervalued, say brokers
Among other auspicious events, the 19th of June marks the end of slavery in the US, Garfield the Cat Day and the birthdays of former British PM Boris Johnson and royal temptress Wallis Simpson.
So why not add a slew of meaningful life sciences announcements, including an HIV vaccine breakthrough, to the June 19 pantheon?
Let's start with Orthocell (ASX:OCC), which reports 'compelling data' showing its Remplir nerve repair agent is superior to suture-only standard techniques.
Stitching accounts for circa 90% of the 700,000 nerve repair procedures done in the US annually.
A cuff that envelops the damaged peripheral nerves, Remplir reduces the use of stitching, which can compromise nerve repair.
Orthocell's study used a rat sciatic nerve injury model, covering 48 rodents across four treatment groups.
These cohorts covered repairs using one, three or six sutures, compared with one suture augmented with Remplir.
The rats' nerve function and regeneration were evaluated up to 12 weeks post-treatment.
The FDA ticked off Remplir in early April and the device is also approved in Canada, Hong Kong, Singapore, New Zealand and here.
Thus, the study was pitched not so much as approval as supporting the US sales rollout.
Orthocell cites a total addressable market in its target markets of US$3.5 billion, with its already-approved geographies accounting for US$1.8 billion.
The US market is worth US$1.6 billion.
Stem-cell hope for bone marrow transplant patients
NeuroScientific Biopharmaceuticals (ASX:NSB) highlights previous clinical data showing its soon-to-be acquired stem cell platform is effective in preventing graft-versus-host disease (GvHD).
The company is buying the asset, Stemsmart from the unlisted Perth-based Isopogen.
The phase I work covered adults and children with life-threatening, steroid-resistant GvHD, a common complication of bone-marrow transplants.
The data shows the treatment is safe and well tolerated, 'with no infusion related toxicities'.
Furthermore, most adults and children had a 'complete or partial resolution of symptoms and improved survival'.
Of the 10 children treated on compassionate grounds, all had survived 12 months post implant. Three of them were still alive six years post treatment.
Turning to pancreatic cancer, Amplia (ASX:ATX) reports another patient with a 'complete response' in its 55-patient trial dubbed Accent.
As close as dammit to a cure, a confirmed complete response formally is defined as all tumour lesions disappearing, with the effect maintained for at least two months.
'This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body,' the company says.
A Singularly fine US deal
Imaging medtech outfit Singular Health Group Ltd (ASX:SHG) has signed a $2 million agreement with a US physician network to develop and use Singular's 3Dicom medical imaging tool.
The compact is with Provider Network Solutions (PNS), covering physician networks in Puerto Rico, Florida, and Texas.
It covers the initial deployment of 1000 3Dicom licences, at US$800 each.
Singular pockets a further US$500,000 on 'satisfaction of AI model marketplace and image repository development and integration'.
The company hope to expand to the remaining 30 states that PNS covers.
3Dicom converts magnetic resonance imaging and computed tomography scans to enable 'immersive visualisation' with three-dimensional images.
Singular also said it had received $8 million of firm commitments in its recently-announced placement.
Meanwhile, microbiome testing house Microba Life Sciences (ASX:MAP) is on trading halt pending a capital raising.
EZZ girds for US launch
Hitherto China and locally focused, health supplements outfit EZZ Life Science (ASX:EZZ) has launched four initial products into the US after winning FDA approval.
To be sold under the new Ezzday banner, the products are made in the US and are tailor-made for American consumers.
Seeing you asked, the remedies cover de-bloating/de-gassing, vaginal probiotics, skincare and colon detox. Readers can draw their own conclusions as to what that means about the State of the Nation in Trumpian times.
Initially, the products will be sold via Amazon and Shopify.
Locally EZZ sells via more than 600 chemists and globally via 750 ecommerce platforms, including China's Douyin and Tmall.
The company values the US supplements market at US$100 billion a year, pipping China's US$80 billion opportunity.
US health secretary Robert F Kennedy Junior (RFK Jr) has a special interest in health supplements, which at the very least shouldn't harm EZZ's US ambitions.
EZZ shares have been on a tear – up 33% over the last month – but they are still well shy of the record $5 peak in October last year.
HIV jab spells hope for end to '45-year pandemic'
Speaking of RFK Jr, the FDA has approved a drug that is meant to protect against HIV with a single administration every six months.
Yep – it's a vaccine – so maybe the health czar isn't as avowedly anti-vaxx as we all think.
Marketed as Yeztugo by Gilead Sciences, lenacapavir is seen as the best hope of knocking HIV – in effect a 45-year pandemic – on its head.
Clinicians say the drug is much more powerful than the current oral treatments and almost 100% effective.
'This is a historic day in the decades-long fight against HIV,' Gilead CEO Daniel O'Day said.
'Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.'
The drug has a list price of US$28,218 ($43,300). But Gilead may provide the vaccine free to non-insured patients.
Have investors underestimated Clarity?
Is radiopharmacy outfit Clarity Pharmaceuticals (ASX:CU6) a case of 'objects in this rear view mirror are closer than you think'?
Following a series of clinical updates from Clarity, broker Canaccord values the company at $6.74 a share, a lofty 210% increment on the current price.
In March, Wilsons ascribed an even ballsier $8.25 a share.
All things being equal – and they never are – that would value Clarity at $2.6 billion.
Sector champ Telix Pharmaceuticals (ASX:TLX) is worth around $8 billion, bearing in mind it has two FDA-approved prostate cancer imaging tools and a kidney cancer consent in the offing.
Yesterday, Clarity said it has struck an agreement with US mob Spectronrx.
Spectronrx will provide 400,000 patient-ready does of its copper isotope based 64Cu-SAR-bisPSMA (for diagnosing and potentially treating prostate cancer).
In the nuclear medicine game, gaining access to nearby doses is half the battle. But this agent's generous half-life means it can be distributed across all 50 US states.
Clarity recently announced promising phase II results for 64Cu-Sartate (neuroblastoma) and 64Cu-SAR-Bombesin (PSMA-negative prostate cancer).
Another program, Secure, focuses on identifying and treating metastatic castration-resistant prostate cancer.
Clarity currently has no approved products, but Canaccord expects 64Cu-SAR-bisPSMA to be on market by mid 2027.
'Recent commercial agreements should remind the market that this potential best-in-class asset could be closer than we think.'
The firm reckons Clarity can win a 20% share of the US market, for US$520m in peak sales.
Your columnist's nuclear science credentials – the ones plucked from a Weeties pack – are out of date.
But it looks like Telix should have one eye on the rear-view mirror and the other on the road ahead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Telegraph
2 hours ago
- Daily Telegraph
Aus company secures $125m order for high power laser weapon
Don't miss out on the headlines from Innovation. Followed categories will be added to My News. An Australian technology company has secured a 'groundbreaking' $125 million deal with a European country for a 'high energy laser weapon system' designed to shoot down over a dozen drones within a minute. Electro Optic Systems (EOS) signed a contract with a European NATO Member State – the name of which has not been disclosed – to deliver the 100-kilowatt anit-drone weapon between 2025-2028. 'The new laser counter-drone capability was developed by EOS to address the urgent market need and emerging strategic requirement to defend against drone swarm attacks at an economical cost,' EOS said in a statement on its website. 'This is the world's first export order for a 100-kilowatt class laser defence system.' The high energy laser weapons was designed to defend against drone swarm attacks. Picture: Supplied/Electro Optic Systems The company said the order, which is valued at €71.4 million (or about $A125 million), will be fulfilled in Singapore, where EOS has a laser innovation centre. 'EOS is already an established global leader in counter-drone capability using kinetic weapons and missiles to bring down drones. The high-power laser builds on these core competencies and substantially extends them.' The system – which is mobile and can work on a truck – operates 'at the speed of light' and can shoot down as many as twenty drones in a minute, Dr Andreas Schwer, Chief Executive Officer of Electro Optic Systems told 'The laser can hit a target almost instantly … unlike a bullet which takes a second to get there,' Dr Schwer said. The order is valued at $A125 million. Picture: Electro Optic Systems The laser can hit a target almost instantly. Picture: Electro Optic Systems He said the system works by amplifying lasers to high power levels. '(It) then combines multiple laser beams together,' he explained. 'It tracks targets very accurately – this is critical – and keeps the laser beam on the target … The light energy typically degrades the drone target in 1-2 seconds.' While missiles generally have a longer range, the high-power laser system 'can shoot down many more targets' at a cheaper cost within a two to five kilometre range. 'Missile systems cost $0.5m – $2.0m per shot fired,' Dr Schwer said. 'The laser system costs less than 10 cents per shot.' 'Lasers can shoot directly upwards, which ballistics (bullets and missiles) often cannot do,' he added. A Russian drone attacks a building during a Russian missile and drone air attack in Kyiv, Ukraine, June 17, 2025. Picture: AP Photo/Efrem Lukatsky With drones becoming increasingly more common in modern warfare and swarms posing a 'real threat', Dr Schwer said militaries will need to employ a 'layered solution', including laser systems, rocket systems and longer-range missiles to protect their valuable assets. 'Drones are a big threat both in military and civil domains,' he said. 'Because drones get cheaper every year, everyone is using them and many valuable assets are very vulnerable.' He noted other countries are trying to develop laser weapon technology, 'but it is very complex'. 'This is the first very international supply contract of this size in the laser weapon industry – a groundbreaking deal for our industry and for EOS,' he said in a video on the company's website. Looking to the future, Dr Schwer said laser weapons will continue to play a role on the battlefield, becoming more powerful and portable over time. Going forward, the company is looking to expand its 50 to 100 kilowatt family and develop systems towards the 150 kilowatt class to meet future needs. 'We are also looking to develop naval variants of our models, giving the critical gap in the market for effective counter-drone solutions.' Russia tests laser defences It comes as Russia last month conducted large-scale tests of new laser systems to defend against drones – which both Ukraine and Russia have deployed during the nations' three year war. 'These technologies will form one of the key elements of the universal air defense system President Vladimir Putin recently called for,' the Board of the Military-Industrial Complex said in a statement. 'The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons.' Russian soldiers prepare a strike FPV drone aircraft to fly towards Ukrainian position in an undisclosed location. Picture: Russian Defense Ministry Press Service/AP Meanwhile, Ukraine last year announced it had developed its own laser weapon which can target and down aircraft at altitudes exceeding two kilometres. Speaking at the 'European Defense Industry: Prospects for Cooperation with the Ukrainian Defense Industry' conference in December, Colonel Vadym Sukharevskyi said the country's military proudly declared Tryzub (trident) 'laser is real and operational', adding that efforts were underway to scale up its capabilities against Russia. Colonel Sukharevskyi also introduced the concept of 'mother drones' or 'queen drones' — unmanned aerial systems capable of carrying two FPV (first-person view) light attack drones during his address. According to the Kyiv Independent, the announcement marked a significant leap in Ukraine's military innovation. Originally published as 'Speed of light': Australian company secures 'groundbreaking' $125m order for high power anti-drone weapon
News.com.au
3 hours ago
- News.com.au
‘Speed of light': Australian company secures ‘groundbreaking' $125m order for high power anti-drone weapon
An Australian technology company has secured a 'groundbreaking' $125 million deal with a European country for a 'high energy laser weapon system' designed to shoot down over a dozen drones within a minute. Electro Optic Systems (EOS) signed a contract with a European NATO Member State – the name of which has not been disclosed – to deliver the 100-kilowatt anit-drone weapon between 2025-2028. 'The new laser counter-drone capability was developed by EOS to address the urgent market need and emerging strategic requirement to defend against drone swarm attacks at an economical cost,' EOS said in a statement on its website. 'This is the world's first export order for a 100-kilowatt class laser defence system.' The company said the order, which is valued at €71.4 million (or about $A125 million), will be fulfilled in Singapore, where EOS has a laser innovation centre. 'EOS is already an established global leader in counter-drone capability using kinetic weapons and missiles to bring down drones. The high-power laser builds on these core competencies and substantially extends them.' The system – which is mobile and can work on a truck – operates 'at the speed of light' and can shoot down as many as twenty drones in a minute, Dr Andreas Schwer, Chief Executive Officer of Electro Optic Systems told 'The laser can hit a target almost instantly … unlike a bullet which takes a second to get there,' Dr Schwer said. He said the system works by amplifying lasers to high power levels. '(It) then combines multiple laser beams together,' he explained. 'It tracks targets very accurately – this is critical – and keeps the laser beam on the target … The light energy typically degrades the drone target in 1-2 seconds.' While missiles generally have a longer range, the high-power laser system 'can shoot down many more targets' at a cheaper cost within a two to five kilometre range. 'Missile systems cost $0.5m – $2.0m per shot fired,' Dr Schwer said. 'The laser system costs less than 10 cents per shot.' 'Lasers can shoot directly upwards, which ballistics (bullets and missiles) often cannot do,' he added. With drones becoming increasingly more common in modern warfare and swarms posing a 'real threat', Dr Schwer said militaries will need to employ a 'layered solution', including laser systems, rocket systems and longer-range missiles to protect their valuable assets. 'Drones are a big threat both in military and civil domains,' he said. 'Because drones get cheaper every year, everyone is using them and many valuable assets are very vulnerable.' He noted other countries are trying to develop laser weapon technology, 'but it is very complex'. 'This is the first very international supply contract of this size in the laser weapon industry – a groundbreaking deal for our industry and for EOS,' he said in a video on the company's website. Looking to the future, Dr Schwer said laser weapons will continue to play a role on the battlefield, becoming more powerful and portable over time. Going forward, the company is looking to expand its 50 to 100 kilowatt family and develop systems towards the 150 kilowatt class to meet future needs. 'We are also looking to develop naval variants of our models, giving the critical gap in the market for effective counter-drone solutions.' Russia tests laser defences It comes as Russia last month conducted large-scale tests of new laser systems to defend against drones – which both Ukraine and Russia have deployed during the nations' three year war. 'These technologies will form one of the key elements of the universal air defense system President Vladimir Putin recently called for,' the Board of the Military-Industrial Complex said in a statement. 'The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons.' Meanwhile, Ukraine last year announced it had developed its own laser weapon which can target and down aircraft at altitudes exceeding two kilometres. Speaking at the 'European Defense Industry: Prospects for Cooperation with the Ukrainian Defense Industry' conference in December, Colonel Vadym Sukharevskyi said the country's military proudly declared Tryzub (trident) 'laser is real and operational', adding that efforts were underway to scale up its capabilities against Russia. Colonel Sukharevskyi also introduced the concept of 'mother drones' or 'queen drones' — unmanned aerial systems capable of carrying two FPV (first-person view) light attack drones during his address. According to the Kyiv Independent, the announcement marked a significant leap in Ukraine's military innovation.
ABC News
6 hours ago
- ABC News
US to charge some foreign travellers up to $23,000 in visa bonds
The US Department of State has prepared plans to impose bonds of up to $US15,000 ($23,000) for some tourist and business visas, according to a preview of the notice. The 12-month pilot program will give US consular officers the discretion to issue bonds to visitors from countries identified as "having high visa overstay rates," the notice to be published on Tuesday, local time, said. It added that bonds could also be applied to countries "where screening and vetting information is deemed deficient, or offering Citizenship by Investment, if the alien [applicant] obtained citizenship with no residency requirement". But the notice does not specify the countries that meet this requirement, noting "until the Pilot Program countries are selected, the Department is unable to estimate the number of visa applicants that will fall within the scope". The pilot visa program is expected to take effect in two weeks, on August 20, and last a whole year. Consular officers will have three options for visa applicants subjected to the bonds: $US5,000, $US10,000 or $US15,000, but will generally be expected to require at least $US10,000, the notice said. Travellers will get their bonds back when they depart the US in accordance with the terms of their visas. If they do not comply, the bond deposit will be forfeited. The US State Department said in the notice that the pilot program would help assess the feasibility of processing and discharging bonds for tourist and business visas. It would also "inform any future decision concerning the possible use of visa bonds to ensure nonimmigrants using these visa categories comply with the terms and conditions of their visas and timely depart the United States". Further, if the program is deemed feasible, the department said "it would serve as a critical diplomatic tool to compel other countries to address overstays by their nationals and to address deficiencies in their identity verification standards". The proposal comes as President Donald Trump's administration cracks down on immigration to the US and tightens requirements for visa applicants. He issued a travel ban in June that fully or partially blocks citizens of 12 countries from entering the US on national security grounds, mainly impacting people from the Middle East and Africa. While the State Department is currently unable to estimate the number of applicants to be impacted by the visa bond policy, many of the countries targeted by Mr Trump's travel ban also have high rates of visa overstays. This could mean Chad, Eritrea, Haiti, Myanmar and Yemen will be affected. Other countries with high overstay rates include Burundi, Djibouti and Togo, according to US Customs and Border Protection data from the 2023 fiscal year. The US Travel Association, a group that represents major tourism firms, said in a statement that the scope of the visa bond pilot "appears to be limited," potentially affecting an estimated 2,000 applicants. They will most likely be "from only a few countries with relatively low travel volume to the United States," the association said. Mr Trump's immigration policies have led some visitors to skip travel to the US, with data showing the country is suffering a sharp decline in tourism, including an 11.6 per cent decrease in overseas visitors in March. Meanwhile, the US experienced its sharpest decline in Australian visitors since the height of the COVID pandemic in March this year, with a 7 per cent drop in visitor numbers. The Australian Department of Foreign Affairs (DFAT) has toughened its travel advice for the US multiple times this year in response to the Trump administration's increasingly harsh border controls. While DFAT has not changed the US's overall rating from green, which means "exercise normal safety precautions," it has beefed up warnings about being detained at the border and requirements to carry identification inside the country. "Check US entry, registration, transit and exit requirements," it advises Australian travellers. "Whether you're travelling on a visa or under the Visa Waiver Program, ensure you understand all relevant terms and conditions before attempting to enter the United States."
